FADAA/DCF VIVITROL PROGRAM - Florida Alcohol and Drug

FADAA/DCF VIVITROL
PROGRAM
How to Apply
Teleconference # 1-877-668-4490
Access Code: 669 622 023
Listen Only Mode
Please note:
As an attendee you are in “listen only mode” and will not be able to verbally
communicate during the webinar.
If you have questions, type your questions or comments in the Q&A or Chat
panel and they will be addressed later.
Technical Issues
• Our audio is being broadcast through the internet to your computer. You must have
speakers attached to your computer and have the correct software and the volume
on. This is the most cost effective method of delivery. The fidelity of this depends on
everyone’s connections speeds; the presenters, mine and yours.
• If you experience poor audio or lose audio, try this first:
Click on the STOP button on the floating AUDIO panel.
Go : COMMUNICATE MENU> AUDIO BROADCAST.
• If you continue to experience a loss of audio or poor audio, try joining the
teleconference: COMMUNICATE MENU/JOIN TELECONFERENCE
• The teleconference call-in toll-free number (US/Canada):
1-877-668-4490
Access code: 669 622 023
FADAA/DCF VIVITROL
PROGRAM
How to Apply
Teleconference # 1-877-668-4490
Access Code: 669 622 023
INTRODUCTION
The 2015 Florida Legislature appropriated $1.5 million in recurring general revenue funds for the Florida
Department of Children and Families (DCF) to continue providing medication assisted treatment,
naltrexone extended-release injectable medication (VIVITROL), to treat alcohol and opioid addicted
individuals being served in community based drug treatment programs.
The DCF has contracted with the Florida Alcohol and Drug Abuse Association (FADAA) to enable providers to
access and receive reimbursement for this medication. The funds will be used to reimburse providers for
Naltrexone (VIVITROL) screening, assessment, and medication administration at the following rate:
Reimbursable
Unit Price
Naltrexone Screening/Medication
Education
$150
Naltrexone Assessment (Physical Exam,
Medication
$540
Administration of Medication (Medical
Management, Medication Administration,
Lab Work and Medication)
$1331
Provider Eligibility
• Be under a subcontract with a Managing Entity (M.E.), as defined in s.
•
•
•
•
394.9082, F.S. for the provision of substance abuse treatment services;
Be currently licensed under s. 397.427, F.S. and Rule 65D-30.014, F.A.C. for
the provision of medication assisted treatment;
Implement medication receiving, storage, and administration procedures that
meet FDA approved prescribing instructions, exceptions, and exclusions;
Have medical staff on site or under contract to meet the medical protocols
for prescribing, storing, dispensing, administering, and monitoring client use
of VIVITROL;
Provide medication assisted treatment using VIVITROL in combination with
counseling and behavioral therapies, to provide a holistic approach to the
treatment of substance abuse according to an individual treatment plan
developed by the subcontracted provider;
Provider Eligibility cont…
• Subcontracted provider must be in good standing with their M.E.; and
• Must be registered with the DCF SAMH Data System and submit data to the
system through their respective ME and the FADAA VIVITROL Program Portal;
• Documentation that your organization has the appropriate health care
practitioners on your staff to:
• Assess individuals for the appropriate use of VIVITROL including the
ability to conduct medical baseline evaluations and required lab;
work to detect active liver disease;
• Prescribe the medication (physician);
• Store the medication;
• Dispense and administer the medication;
• Medically monitor the use of VIVITROL;
• Conduct a clinical assessment.
Provider Eligibility cont...
• Documentation that your organization’s Florida-licensed physician has at least one of
the following credentials or experience levels:
•
•
•
•
Certification in Addiction Medicine
Active in Addiction Medicine Fellowships
Psychiatrist with a Certificate in Addiction
Trained in the Administration of VIVITROL
Training Resource
Medication Assisted Treatment in Substance
Abuse Disorders: Extended Release Naltrexone
(XR-NTX; VIVITROL Webinar by Dr. David
Gastfriend: www.fadaa.org/resource_center/
webinars.php
• Documentation that your agency has implemented medication receiving, storage, and
administration procedures that meet FDA-approved prescribing instructions,
exceptions, and exclusions including refrigeration needed to store VIVITROL at a
temperature between 2-8 degrees Celsius or 36-46 degrees Fahrenheit;
• Documentation that your agency has the capacity to detox or refer a client for
contractual detox services and the capacity to perform on site or through contract
the required laboratory services and to monitor individuals for 7-10 days of
abstinence following detox prior to placing them on VIVITROL;
• Documentation of insurance coverage for all actions of your organization related to
services provided pursuant to this agreement in the minimum amount of
$1,000,000.00 per occurrence and $3,000.000.00, aggregate;
Client Eligibility
• Clients under this contract shall be eligible for publicly funded behavioral
health services, under section 394.674 F.S., and have an alcohol or opioid
dependency
• Clients shall be 18 years of age or older
• Clients shall have a primary diagnosis of alcohol dependence or opioid
dependence disorder as determined by the subcontracted providers subject
to the provisions of Chapter 394 and 397, F.S.
How to access the application – 2 ways
Go to the FADAA website
link at:
https://portal.fadaa.org
Go to the FADAA homepage
at www.fadaa.org and click
on the VIVITROL icon
Introduction
Registration/Sign-In
Contact Information
The FADAA protocol is available at
www.fadaa.org/vivitrol.index.php
If you choose to use your agencies
protocol, you will be prompted to
upload your medical protocol
If yes, you will be
prompted to
enter the name
of the laboratory
Application Part 2 cont…
Application Part 2 cont…
Review & Submit
(CEO and Medical Director)
Congratulations!
Next Steps
After review, an automated response will be sent to the
contact on the application with the status of the agencies
application. If it is rejected a reason will be listed in the email
and a phone call will also be made to the contact. In all cases,
a call will be made to the contact listed on the application for
clarification before the final status response is emailed.
After your agency is approved for the FADAA/DCF VIVITROL
Program, your agency will be required to sign a Memorandum of
Agreement (MOA). The MOA must be signed by your agencies
Executive Director/CEO and FADAA’s Executive Director.
Once the MOA is signed by both agencies, a copy will be
emailed to your agency along with the information your agency
will need to begin entering data to receive reimbursement for
VIVITROL services provided.
TIPS
9 Gather all the data you need before starting the application process. The
pages will time out if it is idles too long and the data will not be saved.
9 If you receive a validation error and the validation error box does not
disappear after you fix the error, close the box by simply clicking on the “X”
in the upper right corner of the red validation box.
9 Before clicking the “previous button,” ensure that you click the save or
continue button on the current page or you will lose the data that was
entered on the page.
For additional information or questions
about the DCF VIVITROL Program, please
contact:
Vanessa M. Addison
FADAA/DCF VIVITROL Program Director
(850) 878-2196 or
vaddison@fadaa.org